Skip to content
It's time to build
Nav Opener
  • Portfolio
  • Team
  • Focus Areas
    • American Dynamism
    • Bio + Health
    • Cultural Leadership Fund
    • Consumer
    • Crypto
    • Enterprise
    • Fintech
    • Games
    • Growth
    • Talent x Opportunity
  • Content
    Topics
    • Fintech
    • Gaming & Social
    • Security & Privacy
    • Marketplaces
    • Enterprise & SaaS
    • Bio + Health
    • Creator Economy
    • Cryptocurrencies & Blockchains
    Type
    • Articles
    • Video
    • Podcasts
    • Newsletters
  • About
  • Jobs
Close

Vijay Pande

Vijay Pande Download Photo

Vijay Pande, PhD, is a general partner at Andreessen Horowitz, where he focuses on investments in biopharma and healthcare. As the founding investor of a16z’s Bio Fund, Vijay leads the firm’s investments at the cross section of biology and computer science, including applications in computation, machine learning, and artificial intelligence in healthcare; digital therapeutics; diagnostics; and other novel transformative scientific advances applied to industry that take bio beyond healthcare. Op-eds by Vijay defining trends and issues in this emerging space have been published by The New York Times, Scientific American, and Forbes, among others. He is also an Adjunct Professor of Bioengineering at Stanford University.

Previously, Vijay was the Henry Dreyfus Professor of Chemistry and Professor of Structural Biology and of Computer Science at Stanford University, where he led a team of researchers pioneering computational methods and their application to medicine and biology (resulting in over 300 publications, two patents, and two novel drug candidates). Vijay was also concurrently the director of the Biophysics program at Stanford, where he led a team of more than 50 faculty members and propelled the program to the top in the country.

During his time at Stanford, Vijay co-founded Globavir Biosciences, where he translated his research advances into a successful startup that aimed to discover cures for Dengue Fever and Ebola. Vijay also founded the [email protected] Distributed Computing Project for disease research, which pushed the boundaries of computer science techniques (distributed systems, machine learning, and exotic computer architectures) into biology and medicine, in both research as well as the development of new therapeutics.

Vijay holds a BA in Physics from Princeton University and a PhD in Physics from MIT. He has been awarded the DeLano Prize in Computation; a Guinness World Record for [email protected]; the American Chemical Society Thomas Kuhn Paradigm Shift Award; and was selected for MIT TR10. In his teens, Vijay was the first employee at video game startup Naughty Dog Software, maker of Crash Bandicoot.

Pande serves on the boards of Apeel Sciences, BioAge, Devoted Health, Freenome, Insitro, Nobell, Omada Health, Q.bio, and Scribe Therapeutics.

Latest Posts

Investing in SCiFi Foods

by Vijay Pande
  • bio + health

New Year, New Fund, New Opportunities in Bio + Health

by Vineeta Agarwala, Jorge Conde, Justin Larkin, Vijay Pande, Becky Pferdehirt, Jay Rughani, Judy Savitskaya, Daisy Wolf, and Julie Yoo
  • bio + health
  • announcements
  • gene editing including CRISPR
  • healthcare
  • therapeutics
  • when science becomes engineering

The Coming Age for Tech x Bio: The ‘Industrial Bio Complex’

by Vijay Pande
  • bio + health
  • how innovation happens

a16z Podcast: Uncontrolled Spread: Science, Policy, Institutions, Infrastructure

by Scott Gottlieb, Vineeta Agarwala, Marc Andreessen, and Vijay Pande
  • bio + health
  • policy & regulation
  • book launches (and book pods)
  • coronavirus & the COVID-19 pandemic
  • supply chains, logistics, and infrastructure
  • vaccines

From @vijaypande

Vijay Pande@vijaypande

[email protected] is now providing access to our technology for a select group of collaborators. Currently, we are exploring research across a wide range of fields, including oncology, neuroscience, infectious disease, immunology, and cardiology. https://t.co/tduIp26E4k

Vijay Pande@vijaypande

IDRx aims to pioneer intelligently designed combination therapies that hammer driver mutations, cover escape pathways and safely enable use earlier in the course of disease where there is the highest potential for prolonged, durable responses to cancer treatment. Jab-cross-hook! https://t.co/rIMOF9Egts

Iman Abuzeid MD@ImanAbuzeid

There’s very little healthcare-specific marketplace content available, thank you @JayRughani @vintweeta @a16z for producing this, I enjoyed sharing our learnings from @JoinIncredible . Marketplace leaders, or anyone building health tech, check it out 👇🏿 https://t.co/Z62r70mRgZ

Software is eating the world
© 2022 Andreessen Horowitz
Software is eating the world
    • Twitter
    • Simplecast
  • Contact
  • Jobs
  • Briefings
  • Terms of Use & Privacy
  • Disclosures
  • Conduct
  • Who We Are